Abstract
Cervical cancer is the second leading cause of cancer in women worldwide. Human papillomavirus (HPV) is responsible for all cases of cervical cancer. Commercial prophylactic HPV vaccines are now available, but unfortunately these vaccines have no therapeutic effect against established HPV infections. In order to accelerate the control of cervical cancer and treat established HPV infections, it is necessary to develop therapeutic vaccines to eradicate HPV by generating cell-mediated immunity against HPV infected cells. Two HPV-encoded early proteins, the E6 and E7 oncoproteins, are the preferred targets because they are consistently expressed in virtually all cervical cancer cells and are necessary for the induction and maintenance of HPV-associated disease. A variety of vaccine strategies have been employed targeting immune responses to these proteins. Peptide-based vaccines are a promising strategy for the development of therapeutic HPV vaccines because of their safety, stability, and ease of production. This review summarizes the prospects of peptidebased vaccines for the treatment of established HPV infections. We address the challenges that scientists currently face for developing peptide-based vaccines and explore feasible strategies for improving the potency of the induced immune response with the aim of treating established HPV infections.
Keywords: Peptide subunit vaccine, anticancer vaccine, therapeutic vaccine, cervical cancer, human papillomavirus, HPV-16, Commercial prophylactic, HPV infections, cervical cancer cells, peptidebased vaccines, cervical cancer, chemotherapy
Current Topics in Medicinal Chemistry
Title:Advances in Peptide-based Human Papillomavirus Therapeutic Vaccines
Volume: 12 Issue: 14
Author(s): Tzu-Yu Liu, Waleed M. Hussein, Istvan Toth and Mariusz Skwarczynski
Affiliation:
Keywords: Peptide subunit vaccine, anticancer vaccine, therapeutic vaccine, cervical cancer, human papillomavirus, HPV-16, Commercial prophylactic, HPV infections, cervical cancer cells, peptidebased vaccines, cervical cancer, chemotherapy
Abstract: Cervical cancer is the second leading cause of cancer in women worldwide. Human papillomavirus (HPV) is responsible for all cases of cervical cancer. Commercial prophylactic HPV vaccines are now available, but unfortunately these vaccines have no therapeutic effect against established HPV infections. In order to accelerate the control of cervical cancer and treat established HPV infections, it is necessary to develop therapeutic vaccines to eradicate HPV by generating cell-mediated immunity against HPV infected cells. Two HPV-encoded early proteins, the E6 and E7 oncoproteins, are the preferred targets because they are consistently expressed in virtually all cervical cancer cells and are necessary for the induction and maintenance of HPV-associated disease. A variety of vaccine strategies have been employed targeting immune responses to these proteins. Peptide-based vaccines are a promising strategy for the development of therapeutic HPV vaccines because of their safety, stability, and ease of production. This review summarizes the prospects of peptidebased vaccines for the treatment of established HPV infections. We address the challenges that scientists currently face for developing peptide-based vaccines and explore feasible strategies for improving the potency of the induced immune response with the aim of treating established HPV infections.
Export Options
About this article
Cite this article as:
Liu Tzu-Yu, M. Hussein Waleed, Toth Istvan and Skwarczynski Mariusz, Advances in Peptide-based Human Papillomavirus Therapeutic Vaccines, Current Topics in Medicinal Chemistry 2012; 12 (14) . https://dx.doi.org/10.2174/156802612802652402
DOI https://dx.doi.org/10.2174/156802612802652402 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Strategy of Cancer Targeting Gene-Viro-Therapy (CTGVT) a Trend in Both Cancer Gene Therapy and Cancer Virotherapy
Current Pharmaceutical Biotechnology Cancer Drug Development Using Glucose Metabolism Radiopharmaceuticals
Current Pharmaceutical Design New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in Cancer
Current Pharmaceutical Design Potential Applications of <i>Sarcopoterium Spinosum</i> as Medicinal Plants: Overview and Future Trends
Current Traditional Medicine The Chlorophyll Catabolite Pheophorbide a as a Photosensitizer for the Photodynamic Therapy
Current Medicinal Chemistry Mechanism of Action and Therapeutic Potential of Novel Adamantyl Retinoid-Related Molecules
Current Cancer Therapy Reviews Influenza and Stroke Risk: A Key Target Not to be Missed?
Infectious Disorders - Drug Targets Multifunctional Lipoic Acid Conjugates
Current Medicinal Chemistry Biomarkers of Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD), A Review of Published Patents and Patent Applications
Recent Patents on Biomarkers The Immunological Side-Effects of Sedative Agents in the Intensive Care Unit
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry p53-Induced Apoptosis and Inhibitors of p53
Current Medicinal Chemistry ADAMTS9-AS2: A Functional Long Non-coding RNA in Tumorigenesis
Current Pharmaceutical Design Solubility Enhancement and Delivery Systems of Curcumin a Herbal Medicine: A Review
Current Drug Delivery TWIST1 Gene: First Insights in Felis catus
Current Genomics Azathioprine in Multiple Sclerosis
Mini-Reviews in Medicinal Chemistry Compounds From Celastraceae Targeting Cancer Pathways and Their Potential Application in Head and Neck Squamous Cell Carcinoma: A Review
Current Genomics Recent Advances in Diagnostic and Therapeutic Approaches for Breast Cancer: A Comprehensive Review
Current Pharmaceutical Design Volatilome Metabolomics and Databases, Recent Advances and Needs
Current Metabolomics Molecular and Clinical Analysis of Predictive Biomarkers in Non-Small-Cell Lung Cancer
Current Medicinal Chemistry Risk for Cervical Intraepithelial Neoplasia in Systemic Lupus Erythematosus is not Related to Disease Severity
Current Rheumatology Reviews